Information on notice of extraordinary general meeting of iCellate Medical AB (556860-8284) (publ)

Report this content

The shareholders of iCellate Medical AB (publ) are hereby informed that the company has issued notice of an extraordinary general meeting on 27 October 2023 at 1:00 p.m. The meeting takes place at Industrivägen 1 in Solna.

The notice has taken place through advertising in Post- and Inrikes Tidningar and by making the notice available on the company's website; www.icellate.com.

The notice is sent free of charge to shareholders who request it and state their postal address. Such a request can be made in the same way as notification to the general meeting must be made as described below.

Shareholders who wish to participate in the general meeting must be entered in the share register as of October 15, 2023, and register with the company for participation in the general meeting by October 25, 2023 at the latest.

Registration must be done by e-mail to info@icellate.se. When reporting, the name, personal identity number or organization number, address, telephone number and, where applicable, information about a deputy, agent or assistant must be given.

Pelle Redare
CEO
iohn.ryott@icellate.se
iCellate is a Swedish life science company founded in 2011 with its laboratory and office located in Stockholm. iCellate develops cancer diagnostic services across the cancer lifecycle, from hereditary cancer risk (GeneMate®) to early detection, treatment prediction and treatment monitoring (CellMate®). The technologies are based on research from the Karolinska Institute in collaboration with the Karolinska University Hospital.

Subscribe

Media

Media